Full Breakdown
Bepi Shows Functional Cure in Late-Stage Hepatitis B Trials
5/29/2026, 12:30:51 AM
Core Trial Results: Functional Cure in One-Fifth of Patients
Two Phase 3 B-Well 1 and B-Well 2 studies enrolled 1,838 adults with chronic hepatitis B. Participants received weekly injections of bepirovirsen for 24 weeks while continuing standard oral antivirals. A “functional cure” – undetectable HBV DNA and surface antigen six months after stopping the drug – was achieved by 19-20 % of bepirovirsen recipients; no placebo patient was cured. Among participants whose baseline surface antigen was <=1,000 IU/ml, cure rates rose to 25-28 %.
Background: Chronic Hepatitis B and Existing Therapies
Chronic hepatitis B infects roughly 250-300 million people worldwide and can progress to cirrhosis, liver cancer, or death. Current nucleoside/nucleotide analogues suppress viral replication but rarely eliminate the virus, delivering functional cures in only 1-4 % of patients and requiring lifelong daily dosing.
Key Players and Partnerships
- GlaxoSmithKline (GSK) – co-developer, licensor of the drug.
- Ionis Pharmaceuticals – originator of the antisense oligonucleotide.
- Dr. Seng Gee Lim (National University Health System, Singapore) – lead investigator.
- Prof. Jinlin Hou (Guangdong Institute of Hepatology, China) – senior author of the NEJM paper.
- Dr. William Jarnagin (Memorial Sloan Kettering Cancer Center) – external commentator.
- Dr. Anna Lok (University of Michigan) – independent expert.
- Melanie Paff (GSK vice-president) – company spokesperson.
- Analysts Michael Leuchten (Jefferies) and Mani Foroohar (Leerink) provided market commentary.
Data Highlights and Subgroup Performance
- Overall functional cure: 19 % (GSK, Reuters) to 20 % (NYT, AP).
- Low-antigen subgroup (<=1,000 IU/ml): 26 % (GSK) to 28 % (Lee et al.).
- 49 % of all treated patients had surface antigen fall below 100 IU/ml after 12 months.
- Adverse events were mild, chiefly injection-site reactions; transient liver-enzyme elevations occurred in a small minority.
- Trials excluded patients with cirrhosis, HIV co-infection, or very high antigen levels.
Clinical Significance and Market Outlook
A finite six-month regimen could replace lifelong antiviral pills, reducing treatment burden and long-term liver-cancer risk. GSK projects peak annual sales exceeding £2 billion, positioning bepirovirsen as a cornerstone of its target >£40 billion revenue by 2031. The licensing deal with Ionis involved a $25 million upfront payment plus up to $262 million in milestones.
Official Statements & Responses
GSK has filed U.S. FDA, Japanese, Chinese, and European applications, receiving fast-track and breakthrough-therapy designations; a decision is due by Oct 26. The company asserts that bepirovirsen “could markedly lessen the lifelong treatment burden for millions of patients.” Investigators highlighted the drug’s tolerability and its potential to shift standard-of-care protocols.
Criticism, Limitations, and Unanswered Questions
Independent experts note that the excluded populations (cirrhosis, high antigen, HIV) limit generalizability. Long-term durability beyond three years remains uncertain, and real-world implementation may be slowed by the need for baseline antigen screening and infusion-site logistics.
Conflicting Reports & Gaps
Cure rates are reported as 19 % (Reuters, GSK) and 20 % (NYT, AP). Low-antigen subgroup outcomes vary between 25 % and 28 % across sources. No data are available on efficacy in patients with advanced liver disease or co-infections, creating a gap for future research.
Verbatim Quotes
- “It’s the first major advance in the treatment of chronic hepatitis B in decades,” — Dr. William Jarnagin, surgeon, Memorial Sloan Kettering Cancer Center
- “To have six months of injections to achieve functional cure of this magnitude ... is, to me, a great advance in the management of my patients,” — Dr. Seng Gee Lim, lead investigator, National University Health System, Singapore
- “Combined with improved testing and diagnosis, this innovation has the potential to improve the lives of millions living with [chronic hepatitis B].” — Prof. Jinlin Hou, Guangdong Institute of Hepatology, China
- “We have not had a treatment which has come to this level of cure,” — Dr. Seng Gee Lim (additional comment)
- “The new drug attacks hepatitis B by binding to its genetic components, suppressing viral replication as well as a key protein, the “S” or surface protein, and stimulates the immune system, said GSK vice president Melanie Paff.” — Melanie Paff, vice-president, GSK
What’s Next: Regulatory Timeline and Potential Launch
The FDA is slated to issue a decision by Oct 26 under priority review; parallel reviews are underway in Japan, China, and the EU. GSK has indicated readiness to launch in the third quarter pending approvals, while post-marketing studies will monitor durability and safety in broader patient groups.
